William Blair Has Positive Forecast for Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Hologic in a note issued to investors on Thursday, February 6th. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will earn $1.12 per share for the quarter, up from their prior estimate of $1.10. William Blair has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic’s Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%.

A number of other brokerages have also issued reports on HOLX. Royal Bank of Canada cut their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $80.00 to $75.00 in a research report on Thursday. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Down 10.1 %

Shares of NASDAQ HOLX opened at $65.45 on Friday. The firm has a market cap of $14.77 billion, a price-to-earnings ratio of 19.65, a PEG ratio of 2.35 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic has a 52-week low of $64.87 and a 52-week high of $84.67. The business’s 50 day moving average is $72.63 and its two-hundred day moving average is $77.86.

Hedge Funds Weigh In On Hologic

Several hedge funds have recently made changes to their positions in the company. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the last quarter. Covestor Ltd grew its holdings in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Brooklyn Investment Group grew its holdings in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the last quarter. Finally, Empirical Finance LLC grew its holdings in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.